INTRODUCTION: Post-transplant lymphoproliferative disease (PTLD) is a series of proliferative diseases of the lymphatic system. Among patients receiving hematopoietic stem cell transplantation (HSCT), PTLD is a prevalent complication that severely affects rates of survival. Ultrasound plays an essential role in the early diagnosis of PTLD. Contrast-enhanced ultrasonography (CEUS) and CEUS-guided biopsy are critical procedures for tumor diagnosis. PATIENT CONCERNS: Herein, we report the case of a 40-year-old male patient with acute lymphoblastic leukemia who received HSCT more than 1 year ago. Sonography revealed a small hypoechoic nodule in the liver four months after HSCT. Eight months after HSCT, larger and more nodules were observed via ultrasound; CT was used to identify the lesions. DIAGNOSES: CEUS and CEUS-guided biopsy were performed, and the pathological diagnosis was PTLD. INTERVENTIONS: The final clinical diagnosis was PTLD, and cyclophosphamide, epirubicin, and dexamethasone were administered as chemotherapy. OUTCOMES: The patient was discharged after his condition improved. CONCLUSION: Ultrasound can be used to effectively detect lesions of PTLD early after HSCT. Furthermore, CEUS and CEUS-guided biopsy were effective for early confirmatory diagnoses of PTLD after HSCT.
INTRODUCTION: Post-transplant lymphoproliferative disease (PTLD) is a series of proliferative diseases of the lymphatic system. Among patients receiving hematopoietic stem cell transplantation (HSCT), PTLD is a prevalent complication that severely affects rates of survival. Ultrasound plays an essential role in the early diagnosis of PTLD. Contrast-enhanced ultrasonography (CEUS) and CEUS-guided biopsy are critical procedures for tumor diagnosis. PATIENT CONCERNS: Herein, we report the case of a 40-year-old male patient with acute lymphoblastic leukemia who received HSCT more than 1 year ago. Sonography revealed a small hypoechoic nodule in the liver four months after HSCT. Eight months after HSCT, larger and more nodules were observed via ultrasound; CT was used to identify the lesions. DIAGNOSES: CEUS and CEUS-guided biopsy were performed, and the pathological diagnosis was PTLD. INTERVENTIONS: The final clinical diagnosis was PTLD, and cyclophosphamide, epirubicin, and dexamethasone were administered as chemotherapy. OUTCOMES: The patient was discharged after his condition improved. CONCLUSION: Ultrasound can be used to effectively detect lesions of PTLD early after HSCT. Furthermore, CEUS and CEUS-guided biopsy were effective for early confirmatory diagnoses of PTLD after HSCT.
Authors: R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg Journal: Blood Date: 1999-10-01 Impact factor: 22.113
Authors: J E Johansson; M Remberger; V Lj Lazarevic; H Hallböök; A Wahlin; E Kimby; G Juliusson; H Omar; H Hägglund Journal: Bone Marrow Transplant Date: 2010-10-18 Impact factor: 5.483
Authors: Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman Journal: Haematologica Date: 2016-07 Impact factor: 9.941
Authors: Samuel Romero; Juan Montoro; Marta Guinot; Luis Almenar; Rafael Andreu; Aitana Balaguer; Isabel Beneyto; Jordi Espí; José Gómez-Codina; Gloria Iacoboni; Isidro Jarque; Rafael López-Andújar; Empar Mayordomo-Aranda; Joaquín Montalar; Amparo Pastor; Miguel Pastor; José L Piñana; Nohelia Rojas-Ferrer; Ignacio Sánchez-Lázaro; Jesús Sandoval; Guillermo Sanz; Miguel Á Sanz; Amparo Solé; Jaime Sanz Journal: Leuk Lymphoma Date: 2018-07-03